Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Medicine Matters oncology

Dr Richard Finn is a Professor of Clinical Medicine in the Department of Medicine, Division of Hematology/Oncology at the Geffen School of Medicine. He is also Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, UCLA.

Dr Finn’s research interests lie in the development of molecular targeted agents and biomarkers in liver and breast cancer, with a particular interest in identifying predictive markers of response to novel therapeutics. He has served as principal and sub-investigator in trials exploring the use of targeted therapies, and has led the approval of palbociclib, the first CDK 4/6 inhibitor in cancer medicine. Dr Finn’s work has been widely published in respected journals, and he is a Senior Editor of Clinical Cancer Research and on the editorial boards of the Journal of Hepatology and Liver Cancer.

Dr Finn is a member of the American Society of Clinical Oncology, American Association of Cancer Research and the European Society of Medical Oncology and has presented at major meetings organised by such societies (ECCO / ESMO / ASCO / AACR). He is also the immediate past President of the International Liver Cancer Association.